Skip to main content
Chemomab Therapeutics Ltd. logo

Chemomab Therapeutics Ltd. — Investor Relations & Filings

Ticker · CMMB ISIN · US16385C1045 US Manufacturing
Open in API
Filings indexed 332 across all filing types
Latest filing 2021-10-26 Declaration of Voting R…
Country US United States of America
Listing US CMMB

About Chemomab Therapeutics Ltd.

https://www.chemomab.com/

Chemomab Therapeutics Ltd. is a clinical-stage biotechnology company developing therapeutics for fibro-inflammatory diseases with high unmet medical needs. The company's scientific platform is based on the discovery of the soluble protein CCL24's central role in driving the cycle of fibrosis and inflammation. Its lead product candidate, nebokitug (CM-101), is a first-in-class monoclonal antibody designed to neutralize CCL24, thereby interfering with the primary pathways that promote these conditions. Nebokitug has demonstrated disease-modifying potential in multiple clinical trials and has received Orphan Drug and Fast Track designations from the U.S. FDA for the treatment of primary sclerosing cholangitis (PSC). Following positive Phase 2 results, the company is preparing for a potential Phase 3 trial for nebokitug in PSC.

Recent filings

Filing Released Lang Actions
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated October 26, 2021, reporting on a Special General Meeting of Shareholders held on October 25, 2021. The main content is the submission of matters to a vote of security holders, specifically the approval of employment terms for the CEO. The document provides detailed voting results and references the proxy statement filed earlier. The key activity is the announcement of voting results from a shareholder meeting, which aligns with the category 'Declaration of Voting Results & Voting Rights Announcements (DVA)'. The document length is 4421 characters, which is short but contains substantive voting results, not just a report publication announcement. Therefore, the correct classification is DVA with high confidence.
2021-10-26 English
8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, which is used for reporting unscheduled material events or corporate updates. The text specifically mentions that the report includes an updated corporate presentation as Exhibit 99.1. The document length is 3170 characters, which is relatively short and primarily serves as an announcement of the attached presentation rather than the presentation itself. There are no financial statements or detailed financial data included in the text. According to the 'Menu vs Meal' rule, this is an announcement of a report (the corporate presentation) rather than the report itself. Therefore, the appropriate classification is Investor Presentation (IP).
2021-10-25 English
DEF 14A
Proxy Solicitation & Information Statement
2021-09-17 English
S-8
Capital/Financing Update Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans. It includes details about the securities to be registered, the share incentive plan, and references to merger agreements and incorporation of other filings by reference. It is not a financial report, earnings release, or management discussion, but a capital/financing related filing concerning registration of shares for employee plans. Therefore, it fits the Capital/Financing Update (CAP) category.
2021-09-13 English
PRE 14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Proxy Statement filed on Schedule 14A with the SEC, as indicated by the header and references to SEC rules. It is soliciting shareholder votes for a Special General Meeting, specifically for approval of the terms of employment of a new CEO. The text includes detailed voting instructions, meeting logistics, quorum requirements, and voting procedures. It is not an annual report, earnings release, or any financial statement. It is not a voting results announcement but the solicitation of votes. The document is lengthy (15,000 characters) and contains the full proxy statement content, not just a brief announcement or notice. Therefore, it fits the category of Proxy Solicitation & Information Statement (PSI).
2021-09-03 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, dated September 2, 2021, by Chemomab Therapeutics Ltd. The key content is the announcement of the appointment of a new Chief Executive Officer, Dr. Dale Pfost, replacing the previous CEO. It includes biographical details and mentions that the appointment is subject to shareholder approval. The document also references a press release and a corporate presentation as exhibits. The primary focus is on management changes, specifically the appointment of a new CEO and related board changes. There are no financial statements or detailed financial data presented, so it is not an Annual Report, Interim Report, or Earnings Release. It is not a proxy solicitation or voting results announcement. The document fits the category of Board/Management Information (MANG) as it announces changes in senior management and board membership.
2021-09-02 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.